PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it will present Phase 1 clinical data for its investigational drug Teverelix at the American Association of Clinical Endocrinology Annual Meeting, scheduled for April 22–24 in Las Vegas.
The presentation will be delivered by Chief Medical Officer Dr. Faisal Mehmud during a poster session on April 24 at 11:40 a.m. Pacific Time.
Teverelix is a long-acting gonadotropin-releasing hormone antagonist being developed for hormone-driven conditions, including endometriosis and uterine fibroids.
The data come from two Phase 1 studies conducted in Germany involving 48 healthy premenopausal women who received single-dose subcutaneous administration of the drug.
The studies showed dose-dependent suppression of estradiol levels, with some participants reaching ranges considered therapeutically relevant.
Pharmacokinetic results indicated rapid initial absorption followed by sustained drug exposure, with a terminal half-life of approximately 14 to 23 days, supporting the potential for infrequent dosing.
Bone turnover markers remained within normal ranges with limited changes after treatment, and no unexpected safety signals were observed.
The company said the findings support further clinical development of Teverelix in patient populations.
Mehmud will present the findings in a poster titled “Evaluation of Teverelix, a Long-Acting GnRH Antagonist: Pharmacokinetics, Pharmacodynamics, Bone Turnover and Safety in Two Phase I Studies in Healthy Female Volunteer.”
More information is available at https://aace2026.d365.events/education/posters/41c0e4cf-130f-46be-8910-0d7a1b2a8dc1.
Medicus Pharma is a biotechnology company focused on developing therapies for unmet medical needs.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.